Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Satri-cel Consolidation in Resected G/GEJ Adenocarcinoma
NCT06857786Phase 1Not yet recruiting
- Sponsor
- Peking University
- Start
- Mar 2025
- Primary completion
- Jun 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of satricabtagene autoleucel in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Peking University. Primary endpoint: Incidence, type, and severity of adverse events at 15 years. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
satricabtagene autoleucel
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06857786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06857786.